Table 4. Univariate and multivariate analyses of overall survival in all patients with POALs.
| Factors | Relative risk | 95% Cl | P value |
|---|---|---|---|
| Univariate analysis | |||
| Age > 60 years | 9.923 | 1.240–79.387 | 0.031 |
| Locations | |||
| Conjunctiva | 1 | ||
| Orbital | 0.140 | 0.012–1.604 | 0.114 |
| Lacrimal gland | 0.901 | 0.174–4.677 | 0.901 |
| High-grade components | 3.021 | 0.748–12.200 | 0.121 |
| LDH elevation | 2.672 | 0.661–10.799 | 0.168 |
| Ann Arbor stage III–IV disease | 4.039 | 1.005–16.226 | 0.049 |
| AJCC stage T3 and T4 disease | 3.169 | 0.779–12.895 | 0.107 |
| AJCC stage with N1–4 disease | 2.061 | 0.245–17.345 | 0.506 |
| AJCC stage with M1 disease | 2.733 | 0.566–13.191 | 0.211 |
| Multivariate analysis | |||
| Age > 60 years | 37.275 | 2.364–587.675 | 0.010 |
| Ann Arbor stage III–IV disease | 35.884 | 1.162–1108.528 | 0.041 |
Abbreviations: POALs, primary ocular adnexal lymphomas; CI, confidence interval; LDH, lactate dehydrogenase; AJCC, American Joint Committee on Cancer.